Molecular testing, first-line treatment patterns, and survival in metastatic Colombian non–small cell lung cancer: the RECAPC multicenter registry - Takeaways - MDSpire

Molecular testing, first-line treatment patterns, and survival in metastatic Colombian non–small cell lung cancer: the RECAPC multicenter registry

  • By

  • Ricardo Brugés

  • Pedro Ramos

  • Milton Lombana

  • Anderson Osma

  • Néstor Llinás

  • Javier Cuello

  • Andrés Yepes

  • Ray Manneh

  • Anabelly Coronel

  • Rebeca Granadillo

  • Carolina López

  • Álvaro Osorio

  • Daniel Santa

  • Natalia Arango

  • William Mantilla

  • Diego Gómez

  • July 17, 2026

Share

  • 1

    The RECAPC registry included 585 patients with metastatic non-small cell lung cancer, with a mean age of 72 years and 52% female.

  • 2

    Molecular profiling revealed 32.8% of patients had EGFR/ALK alterations, while 47.5% were not tested or had unknown driver status.

  • 3

    First-line treatment patterns included chemotherapy alone (34.4%), targeted therapy (26.7%), and chemo-immunotherapy (21.0%).

  • 4

    Overall survival analysis showed significant differences by driver group, with not tested/unknown status associated with higher mortality.

  • 5

    Incomplete molecular characterization and missing treatment documentation were common, reflecting systemic barriers in Colombian healthcare.

Original Source(s)

Molecular testing, first-line treatment patterns, and survival in metastatic Colombian non–small cell lung cancer: the RECAPC multicenter registry

  • by Ricardo Brugés, Pedro Ramos, Milton Lombana, Anderson Osma, Néstor Llinás, Javier Cuello, Andrés Yepes, Ray Manneh, Anabelly Coronel, Rebeca Granadillo, Carolina López, Álvaro Osorio, Daniel Santa, Natalia Arango, William Mantilla, Diego Gómez

  • July 17, 2026

Related Content

Commentary: Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities

Age-stratified diagnostic performance of the ovarian-adnexal reporting and data system for adnexal masses: a focus on school-age children, early, and middle adolescents

THOR methylation as a pan-cancer mechanism of TERT activation: toward a clinically relevant epigenetic biomarker